Cargando…
Atractylenolide III ameliorates Non-Alcoholic Fatty Liver Disease by activating Hepatic Adiponectin Receptor 1-Mediated AMPK Pathway
Background: Nonalcoholic fatty liver disease (NAFLD) is the most frequent cause of chronic liver diseases worldwide. At present, there are no effective pharmacological therapies for NAFLD except lifestyle intervention-mediated weight loss. Atractylenolide III (ATL III), the major bioactive component...
Autores principales: | Li, Qian, Tan, Jia-Xin, He, Yong, Bai, Fang, Li, Shi-Wei, Hou, Yi-Wen, Ji, Long-Shan, Gao, Ya-Ting, Zhang, Xin, Zhou, Zhen-Hua, Yu, Zhuo, Fang, Miao, Gao, Yue-Qiu, Li, Man |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898375/ https://www.ncbi.nlm.nih.gov/pubmed/35280674 http://dx.doi.org/10.7150/ijbs.68873 |
Ejemplares similares
-
UPLC-MS/MS of Atractylenolide I, Atractylenolide II, Atractylenolide III, and Atractyloside A in Rat Plasma after Oral Administration of Raw and Wheat Bran-Processed Atractylodis Rhizoma
por: Xu, Shizhao, et al.
Publicado: (2018) -
Atractylenolide III ameliorates spinal cord injury in rats by modulating microglial/macrophage polarization
por: Xue, Meng‐Tong, et al.
Publicado: (2022) -
Atractylenolide III inhibits epithelial-mesenchymal transition in small intestine epithelial cells by activating the AMPK signaling pathway
por: Huang, Mingjin, et al.
Publicado: (2022) -
Atractylenolide III Improves Mitochondrial Function and Protects Against Ulcerative Colitis by Activating AMPK/SIRT1/PGC-1α
por: Han, Jieru, et al.
Publicado: (2022) -
The Anticancer Effects of Atractylenolide III Associate With the Downregulation of Jak3/Stat3-Dependent IDO Expression
por: Liu, Jun-bao, et al.
Publicado: (2020)